KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $5.5 billion.

  • Regeneron Pharmaceuticals' Short-term Investments fell 1589.75% to $5.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.5 billion, marking a year-over-year decrease of 1589.75%. This contributed to the annual value of $5.5 billion for FY2025, which is 1589.75% down from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Short-term Investments is $5.5 billion, which was down 1589.75% from $5.9 billion recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Short-term Investments peaked at $8.1 billion during Q4 2023, and registered a low of $1.8 billion during Q2 2021.
  • Moreover, its 5-year median value for Short-term Investments was $5.4 billion (2025), whereas its average is $5.3 billion.
  • In the last 5 years, Regeneron Pharmaceuticals' Short-term Investments soared by 12687.37% in 2022 and then crashed by 3357.5% in 2025.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Short-term Investments stood at $2.8 billion in 2021, then soared by 65.05% to $4.6 billion in 2022, then surged by 75.02% to $8.1 billion in 2023, then fell by 19.6% to $6.5 billion in 2024, then decreased by 15.9% to $5.5 billion in 2025.
  • Its last three reported values are $5.5 billion in Q4 2025, $5.9 billion for Q3 2025, and $5.5 billion during Q2 2025.